Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOS884448 Alone or with Iberdomide +/- Dexamethasone in RRMM
NCT05289492Phase 1Terminated
- Sponsor
- iTeos Therapeutics
- Start
- May 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of belrestotug in multiple myeloma (MM) (3 arms), sponsored by iTeos Therapeutics. Primary endpoints: Number of participants with any adverse events (AEs) and serious adverse events (SAEs), Number of participants with dose limiting toxicity (DLT) and 2 more. Started May 2022; status: terminated.
02
Drugs
belrestotug
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05289492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289492.